The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes con
The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes contacting a therapeutic polypeptide with a concentration of divalent cation between about 5-150 150 mM in a buffer having a pH less than 6.0 and an excipient comprising a sugar or polyol.
대표청구항▼
1. A formulation comprising a buffer having a pH from about 4.8 to about 5.2, a divalent cation, an excipient comprising a sugar or polyol and an effective amount of a therapeutic antibody having specific binding activity to human epidermal growth factor receptor (EGFR), wherein said therapeutic ant
1. A formulation comprising a buffer having a pH from about 4.8 to about 5.2, a divalent cation, an excipient comprising a sugar or polyol and an effective amount of a therapeutic antibody having specific binding activity to human epidermal growth factor receptor (EGFR), wherein said therapeutic antibody is panitumumab or cetuximab and said antibody retains at least about 80% stability for up to two months in solution, and wherein said divalent cation is at least one of CaCl2, ZnCl2, MnCl2 or MgCl2, wherein said divalent cation concentration is selected from about 25 mM, about 50 mM, about 75 mM, about 100 mM, or about 125 mM, and wherein said buffer is at least one of acetic acid, glutamic acid, or succinic acid, or a salt thereof, and wherein said buffer is present in a concentration of about 1 mM to about 50 mM. 2. The formulation of claim 1, wherein said divalent cation is CaCl2. 3. The formulation of claim 2, wherein said CaCl2 concentration is 75 mM. 4. The formulation of claim 1, wherein said sugar or polyol is selected from glycerol, sucrose, trehalose or sorbitol. 5. The formulation of claim 4, further comprising about 1-20% of glycerol, sucrose, trehalose or sorbitol. 6. The formulation of claim 4, further comprising about 1-3% glycerol. 7. The formulation of claim 1, further comprising a surfactant. 8. The formulation of claim 7, wherein said surfactant comprises a polysorbate. 9. The formulation of claim 7, wherein said surfactant is present at a concentration of about 0.001-0.10% (w/v). 10. The formulation of claim 1, further comprising a second excipient. 11. The formulation of claim 10, wherein said second excipient is selected from a buffer, stabilizer, tonicity agent, bulking agent, surfactant, cryoprotectant, lyoprotectant, anti-oxidant, metal ion, chelating agent and preservative. 12. The formulation of claim 1, wherein said therapeutic antibody comprises an Asp or Asn residue susceptible to isomerization to isoaspartic acid. 13. The formulation of claim 1, wherein said therapeutic antibody is present at a concentration of between about 10-200 mg/ml. 14. A method of stabilizing a polypeptide, comprising contacting panitumumab or cetuximab with a concentration of divalent cation in a buffer having a pH from about 4.8 to about 5.2 and an excipient comprising a sugar or polyol, wherein said therapeutic antibody retains at least about 80% stability for up to two months in solution, wherein said divalent cation is at least one of CaCl2, ZnCl2, MnCl2 or MgCl2, and wherein said divalent cation concentration is selected from about 25 mM, about 50 mM, about 75 mM, about 100 mM, or about 125 mM, and wherein said buffer is at least one of acetic acid, glutamic acid, or succinic acid, or a salt thereof, and wherein said buffer is present in a concentration of about 1 mM to about 50 mM. 15. The method of claim 14, wherein said divalent cation is CaCl2. 16. The method of claim 15, wherein said CaCl2 concentration is 75 mM. 17. The method of claim 14, wherein said sugar or polyol is selected from glycerol, sucrose, trehalose or sorbitol. 18. The method of claim 17, wherein said glycerol, sucrose, trehalose or sorbitol comprises a concentration of about 1-20%. 19. The method of claim 17, wherein said glycerol comprises a concentration of between about 1-3%. 20. The method of claim 14, further comprising a surfactant. 21. The method of claim 20, wherein said surfactant comprises a polysorbate. 22. The method of claim 20, wherein said surfactant comprises a concentration of about 0.001-0.10% (w/v). 23. The method of claim 14, further comprising a second excipient. 24. The method of claim 23, wherein said second excipient is selected from a buffer, stabilizer, tonicity agent, bulking agent, surfactant, cryoprotectant, lyoprotectant, anti-oxidant, metal ion, chelating agent and preservative. 25. The method of claim 14, wherein said therapeutic antibody having specific binding activity to human EGFR comprises an Asp or Asn residue susceptible to isomerization to isoaspartic acid.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (39)
Lam Xanthe M. ; Oeswein James Q. ; Ongpipattanakul Boonsri,THX ; Shahrokh Zahra ; Wang Sharon X. ; Weissburg Robert P. ; Wong Rita L., Antibody formulation.
Prestrelski Steven J. (1971 W. Middlefield Rd. ; Unit #5 Mountain View CA 94043) Zhang Mei Z. (444 Via Colinas Thousand Oaks CA 91362), Formulation of a reconstituted protein, and method and kit for the production thereof.
La Zor Clair G. (13054 Rose St. Cerritos CA 90701), Instrument for locating faults in aircraft passenger reading light and attendant call control system.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Loughrey Helen C. (Vancouver CAX) Cullis Pieter R. (Vancouver CAX) Bally Marcel B. (Bowen Island CAX) Choi Lewis S. (Burnaby CAX), Method for protein-liposome coupling.
Colaco Camilo,GBX ; Roser Bruce J.,GBX ; Sen Shevanti,GBX, Method for stabilization of biological substances during drying and subsequent storage and compositions thereof.
Colaco Camilo,GBX ; Roser Bruce J.,GBX ; Sen Shevanti,GBX, Method for stabilization of biological substances during drying and subsequent storage and compositions thereof.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Roemisch, Juergen; Feussner, Annette; Stoehr, Hans-Arnold, Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of ion-exchange chromatography.
Andya James ; Cleland Jeffrey L. ; Hsu Chung C. ; Lam Xanthe M. ; Overcashier David E. ; Shire Steven J. ; Yang Janet Yu-Feng ; Wu Sylvia Sau-Yan, Protein formulation.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.